commun
respiratori
virus
crv
becom
increasingli
recogn
signific
caus
morbid
mortal
among
patient
hematolog
malign
epidemiolog
studi
bacteri
infect
patient
feasibl
cultur
methodolog
prove
reliabl
access
method
investig
limit
avail
highli
sensit
specif
virolog
diagnost
test
made
correspond
data
much
difficult
obtain
advent
nucleicacidbas
test
made
possibl
obtain
posit
diagnos
respiratori
viral
infect
accur
reliabl
quickli
without
reli
special
center
viral
cultur
outcom
intens
treat
hematolog
patient
improv
consist
throughout
year
develop
newer
effect
treatment
regimen
respons
initi
leap
forward
term
surviv
much
progress
made
recent
decad
attribut
improv
support
measur
includ
antibiot
antifung
applic
antivir
treatment
addit
lead
better
toler
aggress
regimen
improv
longterm
surviv
thu
last
two
decad
interest
crv
increas
number
paper
explor
role
respiratori
diseas
immunodefici
patient
note
import
respiratori
virus
associ
found
common
respiratori
virus
influenza
parainfluenza
respiratori
syncyti
viru
rsv
adenovirus
rhinovirus
hrv
coronavirus
also
newli
identifi
virus
human
metapneumovirus
hmpv
bocaviru
hbov
new
strain
coronaviru
find
appli
specif
popul
group
children
elderli
transplant
patient
undergo
immunosuppress
treatment
patient
hematolog
malign
tabl
diseas
caus
virus
vari
selflimit
upper
respiratori
tract
infect
urti
lifethreaten
lower
respiratori
tract
infect
lrti
well
occasion
dissemin
diseas
progress
former
latter
clinic
radiolog
sign
pneumonia
depend
intrins
virul
specif
crv
patientrel
factor
age
underli
ill
type
degre
durat
immun
defici
pneumonia
follow
urti
may
primarili
viral
bacteri
fungal
mix
certain
crv
parainfluenza
frequent
associ
copathogen
respiratori
tract
infect
exhibit
season
share
crv
commun
outbreak
rsv
infect
typic
occur
late
autumn
winter
earli
spring
follow
outbreak
hmpv
influenza
outbreak
gener
take
place
winter
temper
climat
may
occur
throughout
year
tropic
area
parainfluenza
viru
infect
may
appear
throughout
year
outbreak
mainli
occur
spring
summer
autumn
sever
theori
propos
explain
season
increas
crowd
facilit
transmiss
happen
cold
season
lower
temperatur
may
increas
stabil
virion
outsid
bodi
chill
may
increas
host
suscept
lower
temperatur
host
chill
may
activ
dormant
virion
vitamin
defici
preval
winter
due
lower
sun
exposur
better
defin
impact
crv
infect
hematolog
patient
work
group
fourth
european
confer
infect
leukemia
review
literatur
commun
respiratori
virus
januari
made
recommend
accord
infecti
diseas
societi
america
grade
system
diagnosi
crv
infect
made
use
specimen
nasopharyng
aspir
nasopharyng
swab
tracheal
aspir
bronchoalveolar
lavag
main
laboratori
test
use
nucleic
acid
amplif
test
nat
direct
antigen
test
dad
viru
isol
cell
cultur
vic
nat
often
prefer
higher
sensit
shorter
turnaround
time
h
well
possibl
multiplex
nat
capabl
detect
viral
nucleic
acid
asymptomat
patient
becom
import
distinguish
crv
infect
crv
infecti
diseas
effect
group
adapt
case
definit
propos
european
centr
diseas
prevent
control
influenza
viru
crv
patient
leukemia
hematopoiet
stem
cell
transplant
hsct
tabl
tri
updat
review
data
newer
studi
includ
data
influenza
infect
also
tri
add
insight
novel
therapeut
agent
current
use
develop
pipelin
line
find
trend
retrospect
observ
studi
repres
major
public
continu
human
influenza
viru
flu
member
orthomyxovirida
famili
perhap
thoroughli
studi
crv
viru
spheric
sometim
filament
structur
nm
diamet
segment
negativestrand
rna
genom
complex
nucleoprotein
form
nucleocapsid
helic
symmetri
nucleocapsid
enclos
lipid
envelop
two
surfac
glycoprotein
hemagglutinin
neuraminidas
role
pathogenesi
classif
virus
subtyp
import
flu
viru
human
pathogen
well
document
histori
histor
first
gener
agreedupon
influenza
pandem
occur
origin
asia
follow
come
centuri
pandem
russia
china
china
russia
usa
yunnan
provinc
china
hong
kong
mexico
subsequ
pandem
increasingli
acceler
spread
due
advanc
transport
infrastructur
global
pandem
alon
respons
estim
death
toll
million
higher
center
diseas
control
prevent
cdc
made
yearli
estim
flu
death
us
past
sever
decad
inform
last
updat
data
accord
estim
number
influenzarel
death
vari
substanti
depend
year
viru
typesubtyp
age
group
precis
estim
number
flurel
death
due
respiratori
andor
circulatori
caus
rang
season
season
averag
annual
flurel
death
person
age
older
account
approxim
season
promin
influenza
circul
shown
time
death
season
influenza
promin
similar
estim
continent
scale
difficult
obtain
europ
due
larg
dispar
countri
term
diagnosi
surveil
howev
nation
estim
avail
systemat
literatur
review
perform
buchholz
et
al
influenza
pandem
death
germani
estim
influenzarel
mortal
rang
sever
risk
factor
associ
poor
outcom
influenza
infect
lymphopenia
myeloabl
versu
nonmyeloabl
condit
regimen
low
serum
albumin
level
delay
antivir
treatment
risk
benefit
corticosteroid
use
debat
discuss
pandem
laboratoryconfirm
pandem
death
report
world
health
organ
howev
total
mortal
burden
estim
time
higher
surprisingli
high
percentag
death
attribut
person
year
age
consid
estim
cumul
worldwid
incid
billion
peopl
figur
amount
global
mortal
conclus
largescal
studi
avail
estim
pandem
global
impact
hematolog
patient
term
mortal
number
singlecent
studi
show
varieti
result
mortal
appear
similar
gener
popul
greater
durat
hospit
antivir
treatment
hematolog
patient
howev
data
two
european
prospect
survey
show
mortal
hsct
patient
though
design
studi
probabl
identifi
sever
case
anoth
studi
compar
pandem
postpandem
influenza
outbreak
hematolog
patient
show
higher
progress
pneumonia
pandem
group
howev
differ
mortal
likewis
studi
directli
compar
pandem
season
b
influenza
infect
hsct
recipi
show
increas
progress
lrti
hypoxemia
requir
mechan
ventil
patient
infect
pandem
strain
signific
differ
mortal
prompt
antivir
therapi
highdos
steroid
shown
reduc
need
mechan
ventil
convers
shown
corticosteroid
reduc
progress
lrti
mechan
ventil
highdos
corticosteroid
treatment
mgkg
prolong
viral
shed
likewis
martinloech
et
al
show
earli
use
corticosteroid
patient
pandem
influenza
admit
icu
associ
increas
risk
superinfect
human
respiratori
syncyti
viru
rsv
belong
paramyxovirida
famili
contain
continu
singlestrand
negativesens
rna
genom
encapsul
nucleoprotein
phosphoprotein
rnadepend
rna
polymeras
form
ribonucleoprotein
complex
viru
possess
three
membran
protein
receptor
attach
glycoprotein
fusion
protein
short
hydrophob
protein
rsv
infect
occur
yearround
peak
cold
season
mostli
affect
young
children
develop
urti
diseas
rhiniti
laryng
sinus
neonat
risk
lrti
diseas
bronchiol
pneumonia
metaanalysi
reveal
conserv
estim
million
rsvrelat
lrti
worldwid
children
younger
year
roughli
lrti
young
children
result
death
patient
hematolog
malign
andor
hsct
increas
risk
communityacquir
household
nosocomi
transmiss
rsv
infect
occur
pediatr
patient
acut
myeloid
leukemia
children
acut
lymphoblast
leukemia
children
variou
malign
shown
brazilian
group
studi
adult
popul
hematolog
malign
andor
hsct
reveal
incid
rang
tabl
progress
lrti
diseas
report
leukemia
hsct
patient
averag
mortal
rate
patient
hsct
evalu
prospect
singl
influenza
season
switzerland
show
rsv
infect
swab
swab
total
patient
longterm
median
durat
day
rang
day
shed
rsv
demonstr
hsct
recipi
germani
emphas
need
infect
control
nosocomi
transmiss
prevent
measur
risk
factor
progress
lrti
rsv
infect
primarili
found
hostrel
signific
differ
outcom
rsv
serotyp
b
comprehens
systemat
review
conduct
identifi
eight
risk
factor
significantli
associ
rsv
lrti
children
prematur
low
birth
weight
male
sex
sibl
matern
smoke
histori
atopi
lack
breastfeed
crowd
hsct
recipi
smoke
histori
condit
highdos
total
bodi
irradi
absolut
lymphocyt
count
time
urti
onset
significantli
associ
diseas
progress
influenza
corticosteroid
therapi
symptom
onset
urti
shown
damlaj
et
al
significantli
associ
higher
progress
lrti
risk
ratio
rr
p
hospit
admiss
rr
p
icu
admiss
rr
p
mortal
p
month
retrospect
observ
studi
michigan
investig
patient
admit
rsv
infect
signific
increas
morbid
mortal
identifi
patient
hsct
solid
organ
transplant
versu
immunecompet
patient
mortal
higher
howev
patient
year
lymphopenia
admiss
waghmar
et
al
identifi
rsv
rna
detect
plasma
serum
potenti
marker
poor
outcom
hsct
recipi
rsv
lrti
order
facilit
identif
atrisk
hsct
candid
immunodefici
score
index
isi
rsv
develop
measur
six
factor
neutropenia
neutrophilsml
lymphopenia
lymphocytesml
age
year
old
graftversushost
diseas
corticosteroid
use
myeloabl
chemotherapi
time
hsct
base
total
score
hsct
recipi
urti
stratifi
isi
lowrisk
score
mediumrisk
score
highrisk
score
categori
isi
verifi
subsequ
studi
high
score
predict
progress
lrti
posit
predict
valu
urti
caus
rsv
influenza
parainfluenza
adenoviru
without
predict
coronaviru
rhinoviru
human
metapneumoviru
hmpv
negativesens
nonseg
singlestrand
rna
viru
belong
paramyxovirida
famili
identifi
dutch
group
share
mani
similar
rsv
increasingli
recogn
lead
caus
rti
children
adult
sinc
discoveri
seropreval
studi
across
globe
indic
primari
infect
happen
age
virtual
children
infect
age
reinfect
occur
throughout
life
hmpv
demonstr
remark
robust
varieti
mechan
descript
beyond
scope
articl
thoroughli
investig
elsewher
among
immunocompet
host
hmpv
account
crv
infect
studi
done
nashvil
test
nasalwash
specimen
obtain
year
period
otherwis
healthi
children
present
acut
lrti
identifi
hmpv
rna
viabl
specimen
patient
hematolog
malign
hsct
recipi
hmpv
detect
rate
rang
first
year
transplant
systemat
review
includ
studi
publish
shah
et
al
show
incid
hmpv
infect
report
rang
hematolog
malign
hsct
patient
despit
typic
selflimit
infect
gener
popul
report
case
sever
diseas
fatal
outcom
especi
among
hsct
patient
although
frequent
coinfect
make
mortal
directli
attribut
hmpv
difficult
ascertain
among
immunocompet
children
prematur
femal
sex
genotyp
b
infect
associ
sever
hmpv
diseas
cancer
patient
shown
hypoxia
nosocomi
acquir
hmpv
infect
presenc
hematolog
malign
repres
risk
factor
progress
lrti
notabl
studi
mention
risk
factor
tradit
associ
poor
outcom
respiratori
virus
older
age
smoke
histori
corticosteroid
therapi
shown
neg
influenc
outcom
hmpv
infect
human
rhinovirus
hrv
group
positivesens
singlestrand
rna
virus
belong
picornavirida
famili
circul
throughout
year
common
caus
urtid
demonstr
respons
common
cold
larg
benign
immunocompet
patient
role
morbid
mortal
atrisk
popul
come
attent
recent
year
children
hematolog
malign
andor
hsct
hrv
detect
urtid
lrtid
notabl
one
studi
toronto
identifi
hrv
document
rti
pediatr
hsct
recipi
adult
hsct
hrv
maintain
top
posit
insofar
frequenc
concern
reach
cumul
incid
day
posttranspl
identifi
second
frequent
caus
idiopath
pneumonia
syndrom
hsct
patient
repres
detect
pathogen
studi
neutropen
nonhsct
patient
hematolog
malign
follow
month
hrv
detect
patient
nasopharyng
aspir
sampl
five
asymptomat
year
retrospect
studi
new
york
show
hsct
patient
document
hrv
infect
proven
pneumonia
demonstr
coinfect
low
monocyt
count
oxygen
requir
diagnosi
corticosteroid
use
mgkg
identifi
risk
factor
overal
mortal
hrv
infect
human
enterovirus
hev
member
picornavirida
famili
encompass
serotyp
retrospect
studi
patient
hematolog
malign
diagnos
respiratori
infect
hev
hrv
lrti
preset
onset
case
progress
urti
lrti
occur
case
direct
impact
mortal
uncertain
due
frequenc
copathogen
hand
case
report
describ
sever
diseas
fatal
outcom
hsct
patient
hev
sole
identifi
pathogen
import
hev
infect
among
hematolog
patient
may
underst
even
respiratori
virus
enteroviru
first
identifi
sinc
associ
small
outbreak
worldwid
affect
predominantli
children
sever
rang
mild
isol
fatal
includ
one
case
asept
meningomyeloenceph
studi
waghmar
et
al
presum
case
patient
hematolog
malign
outcom
consist
report
infect
respiratori
virus
though
small
number
patient
make
result
difficult
extrapol
notabl
studi
show
patient
test
posit
hrv
infect
fact
infect
proven
sequenc
anoth
enteroviru
identifi
nose
throat
swab
sampl
collect
pediatr
cohort
studi
influenzalik
ill
nicaragua
found
sampl
hsct
recipi
well
sampl
infant
month
old
itali
posit
sampl
hsct
taken
day
transplant
rel
small
group
hematolog
patient
investig
make
impact
popul
group
difficult
fulli
appreci
warrant
larger
studi
human
coronavirus
hcov
belong
coronavirida
famili
larg
envelop
positivestrand
rna
virus
genom
pack
insid
helic
capsid
surround
envelop
three
associ
protein
membran
protein
envelop
protein
involv
viral
assembl
spike
protein
facilit
viral
entri
host
cell
coronavirus
circul
throughout
year
slight
predomin
winter
although
larg
benign
presum
respons
common
cold
abil
anim
human
rapid
interhuman
transmiss
made
one
danger
respiratori
pathogen
new
centuri
exemplifi
sever
respiratori
syndrom
coronaviru
sarscov
peopl
infect
worldwid
within
seven
month
diseas
emerg
fatal
middl
east
respiratori
syndrom
coronaviru
merscov
peopl
infect
fatal
april
hsct
patient
hcov
reach
cumul
incid
day
posttranspl
anoth
studi
identifi
hcov
sampl
posit
respiratori
viru
gather
three
year
period
patient
hcov
identifi
hsct
hematolog
malign
patient
pinana
et
al
found
total
hcov
infecti
episod
hsct
recipi
progress
lrti
lrti
tradit
consid
rare
compar
respiratori
virus
progress
pneumonia
sever
outcom
describ
case
report
recent
data
suggest
mortal
hcov
lrti
may
higher
origin
thought
similar
seen
rsv
influenza
hpiv
infect
ogimi
et
al
demonstr
clinic
outcom
similar
patient
without
respiratori
copathogen
high
viral
load
highdos
steroid
myeloabl
condit
found
associ
prolong
viral
shed
hsct
recipi
infect
hcov
studi
compar
immunocompet
immunocompromis
children
infect
hcov
identifi
multivari
model
younger
age
underli
pulmonari
disord
respiratori
copathogen
especi
rsv
immunocompromis
state
risk
factor
lrti
human
bocaviru
hbov
small
nonenvelop
singlestrand
dna
member
parvovirida
famili
identifi
swedish
group
thu
first
viru
discov
molecular
viru
screen
three
addit
speci
subsequ
discov
ad
genu
name
speci
larg
found
enter
pathogen
associ
upper
lower
respiratori
tract
condit
throughout
globe
studi
compar
hivinfect
hivuninfect
children
lrti
hbov
found
sampl
former
sampl
latter
categori
case
rate
coinfect
least
one
respiratori
viru
high
respect
hbov
infect
detect
patient
hematolog
malign
hsct
though
extent
morbid
mortal
difficult
accur
ascertain
due
high
rate
copathogen
detect
nat
identif
hbov
asymptomat
patient
one
prospect
studi
evalu
children
cancer
diagnos
viral
respiratori
infect
identifi
hbov
rti
etiolog
agent
found
diagnos
lrti
coinfect
virus
pinana
et
al
group
spain
found
hbov
infect
hsct
recipi
progress
lrti
fatal
viral
copathogen
identifi
case
human
parainfluenza
virus
hpiv
medium
size
negativesens
singlestrand
rna
member
paramyxovirida
famili
five
predomin
identifi
serotyp
long
known
togeth
rsv
respiratori
pathogen
primarili
children
caus
mild
urtid
throughout
year
typespecif
season
increas
urtid
lrtid
mainli
laryngotrach
bronchiol
pneumonia
autumn
spring
hpiv
thoroughli
research
epidemiolog
studi
find
respons
one
third
million
lrti
annual
us
children
younger
year
hospit
admiss
lrtid
annual
person
younger
year
approxim
found
caus
crv
interest
hpiv
infect
immunocompromis
patient
gain
momentum
recent
decad
hpiv
report
caus
symptomat
infect
adult
pediatr
hsct
leukemia
patient
least
third
manifest
lrtid
although
typic
selflimit
immunocompet
popul
fatal
outcom
known
occur
patient
leukemia
hsct
mortal
reach
patient
hpiv
pneumonia
anoth
studi
demonstr
strong
associ
pneumonia
mortal
hsct
patient
overal
mortal
reach
day
day
posttranspl
studi
identifi
viral
bacteri
fungal
copathogen
patient
pneumonia
sever
risk
factor
progress
lrti
andor
mortal
hematolog
patient
identifi
srinivasan
et
al
show
hpiv
infect
first
day
posthsct
use
steroid
absolut
leukocyt
count
alc
onset
infect
associ
lrti
africanamerican
ethnic
lrti
use
steroid
mechan
ventil
alc
onset
infect
associ
higher
mortal
ustun
et
al
show
earli
infect
day
hsct
corticosteroid
therapi
presenc
copathogen
associ
higher
mortal
detect
hpiv
lower
respiratori
tract
bronchoalveolar
lavag
lung
biopsi
patient
hpiv
lrti
shown
associ
wors
outcom
detect
hpiv
upper
respiratori
tract
studi
show
multivari
analysi
oxygen
requir
diagnosi
low
monocyt
count
highdos
corticosteroid
therapi
mgkgday
also
associ
high
mortal
either
directli
facilit
coinfect
clear
impact
hpiv
infect
mortal
atrisk
popul
signific
brief
summari
part
data
found
tabl
rapid
develop
resist
amantan
made
class
antivir
obsolet
leav
neuraminidas
inhibitor
effect
therapeut
agent
influenza
infect
nearli
two
decad
concern
potenti
emerg
resist
neuraminidas
inhibitor
address
recent
releas
endonucleas
inhibitor
baloxavir
marboxil
shown
promis
result
oseltamivirresist
strain
still
undergo
clinic
trial
assess
efficaci
administ
associ
neuraminidas
inhibitor
well
safeti
pharmacokinet
efficaci
pediatr
patient
ongo
complet
result
avail
yet
despit
promis
initi
result
concern
may
aris
regard
baloxavir
marboxil
low
genet
barrier
seem
alreadi
lead
emerg
antivir
resist
report
rate
among
immunocompet
adult
adolesc
interestingli
major
patient
resist
occur
appear
infect
strain
wherea
patient
infect
strain
shown
phase
studi
develop
resist
case
suggest
emerg
resist
may
occur
frequent
treatment
strain
sever
agent
activ
influenza
virus
current
investig
compound
target
compon
viral
polymeras
complex
show
promis
three
potenti
target
pa
protein
endonucleas
target
abovement
baloxavir
protein
rnadepend
rnapolymeras
protein
capsnatch
subunit
favipiravir
chemic
inhibitor
shown
broad
activ
influenza
viru
includ
neuraminaseinhibitor
resist
strain
approv
treatment
pandem
flu
japan
furthermor
activ
extend
rna
virus
well
includ
respons
hemorrhag
fever
make
interest
target
studi
potenti
therapeut
option
previous
untreat
diseas
pimodivir
novel
inhibitor
shown
effect
influenza
demonstr
virolog
reduc
viral
shed
nasal
secret
clinic
improv
anoth
inhibitor
schedul
begin
preclin
trial
monoclon
antibodi
target
hemagglutinin
protein
anoth
entic
avenu
research
shown
promis
result
phase
trial
shown
favor
effect
symptom
resolut
viral
replic
adult
uncompl
influenza
infect
current
develop
treatment
sever
influenza
infect
demonstr
dosedepend
antivir
activ
influenza
viru
challeng
model
highest
effect
mg
dose
lower
effect
mg
dose
interestingli
effect
mg
dose
umifenovir
broadspectrum
antivir
current
use
russia
china
cur
prophylact
treatment
influenza
infect
studi
show
experiment
clinic
effect
one
possibl
gener
antivir
agent
investig
uncontrol
trial
aerosol
andor
system
ribavirin
without
intraven
immunoglobulin
associ
proven
safe
administ
appear
effect
prevent
progress
lrti
treatment
pneumonia
caus
rsv
hpiv
although
random
trial
need
confirm
concern
exist
limit
aerosol
ribavirin
regard
environment
exposur
potenti
teratogen
effect
pregnant
healthcar
worker
visitor
special
airflow
requir
high
cost
make
intraven
oral
administr
viabl
altern
palivizumab
monoclon
antibodi
target
rsv
protein
f
also
emerg
potenti
effect
agent
particularli
prophylaxi
rsv
pneumonia
children
adult
increas
risk
sever
diseas
also
treatment
persist
rsv
infect
children
leukemia
improv
outcom
children
rsv
lrtid
investig
novel
agent
met
mix
result
lumicitabin
oral
nucleosid
analogu
prodrug
promis
preliminari
result
start
sever
phase
trial
studi
efficaci
rsv
infect
children
infant
well
one
studi
follow
effect
hospit
adult
metapneumoviru
infect
trial
howev
suspend
sponsor
presatovir
drug
block
rsv
fusion
protein
undergon
sever
trial
studi
effect
gener
popul
hsct
recipi
rsv
urti
lrti
result
yet
publish
ziresovir
oral
bioavail
rsv
fusion
protein
inhibitor
current
undergo
phase
studi
adult
rsv
infect
china
multicentr
studi
pediatr
popul
complet
result
upcom
trimer
nanobodi
bind
antigen
site
ii
rsv
f
protein
high
affin
proven
superior
vitro
neutral
palivizumab
sever
agent
includ
lprotein
nprotein
inhibitor
full
descript
beyond
scope
review
current
studi
describ
elsewher
sever
treatment
option
explor
rhinovir
infect
throughout
year
capsid
binder
capabl
inhibit
viral
entri
consid
promis
agent
show
solid
antivir
activ
vitro
random
trial
howev
show
limit
clinic
benefit
intranas
pirodavir
natur
occur
rhinoviru
cold
howev
reduc
viral
shed
day
benefit
may
interest
patient
underli
haematolog
malign
likewis
pleconaril
whether
oral
intranas
formul
prove
provid
modest
clinic
benefit
reduc
durat
symptom
otherwis
healthi
adult
rhinovir
cold
within
day
also
proven
potenti
benefici
neonat
sever
enteroviru
infect
warrant
research
oral
vapendavir
newer
capsid
binder
recent
fail
prove
superior
placebo
improv
lung
function
reduc
asthma
exacerb
asthmat
patient
howev
result
statist
signific
antivir
effect
demonstr
neg
rv
pcr
administ
within
h
symptom
onset
base
find
phase
trial
studi
vapendavir
treatment
hsct
patient
rv
urti
plan
later
withdrawn
class
antivir
agent
includ
proteas
inhibitor
rupintrivir
nucleosid
analog
inhibitor
phosphatidylinositol
kinas
inhibitor
shown
exhibit
vitro
activ
rhinoviru
type
c
comprehens
studi
util
subgenomicreplicon
infectiousvirusreplicationbas
assay
clinic
benefit
agent
yet
demonstr
hsct
recipientscandid
would
certainli
stand
gain
much
judici
implement
one
treatment
option
regardless
treatment
option
eas
respiratori
virus
transmit
make
enforc
infect
control
measur
critic
reduc
spread
infect
doubli
import
atrisk
popul
group
nosocomi
transmiss
also
common
often
devast
consequ
make
need
adequ
prevent
stringent
addit
deferr
hsct
shown
reduc
risk
progress
pneumonia
group
thorough
review
literatur
made
sever
recommend
manag
crv
infect
hematolog
patient
tabl
two
noninfluenza
crv
infect
potenti
effect
treatment
recommend
made
rsv
hpiv
benefit
aerosol
system
ribavirin
intraven
immunoglobulin
care
taken
case
aerosol
ribavirin
minim
exposur
risk
medic
staff
deferr
therapi
whether
hsct
chemotherapi
appear
viabl
option
patient
crv
respiratori
infect
though
decis
made
casebycas
basi
guidelin
prevent
infecti
complic
among
hematopoiet
cell
transplant
recipi
cosponsor
center
intern
blood
marrow
transplant
research
cibmtr
nation
marrow
donor
program
nmdp
european
blood
marrow
transplant
group
ebmt
american
societi
blood
marrow
transplant
asbmt
canadian
blood
marrow
transplant
group
cbmtg
infecti
diseas
societi
america
idsa
societi
healthcar
epidemiolog
america
shea
associ
medic
microbiolog
infecti
diseas
canada
ammi
cdc
updat
make
sever
indepth
pointbypoint
recommend
gener
infect
control
act
droplet
standard
precaut
specif
measur
target
therapi
ribavirin
palivizumab
rsv
infect
vaccin
neuraminidas
treatment
influenza
infect
summari
recommend
found
tabl
sheer
abund
alon
enough
make
burden
crv
infect
healthcar
system
throughout
world
easili
appar
vast
major
end
selflimit
urti
diseas
impact
global
morbid
mortal
neglig
hematolog
patient
definit
atrisk
popul
make
lot
number
insofar
mortal
concern
potenti
fatal
outcom
report
benign
crv
technolog
leap
recent
decad
greatli
improv
knowledg
virus
facilit
diagnosi
longterm
solut
consist
effect
treatment
option
support
largescal
studi
adequ
prophylaxi
measur
vaccin
continu
elud
us
cibmtr
nmdp
ebmt
asbmt
cbmtg
idsa
shea
ammi
cdc
guidelin
exampl
progress
made
prevent
treatment
mani
therapeut
agent
current
investig
despit
yet
provid
definit
solut
increasingli
glare
problem
repres
first
step
find
remedi
microorgan
previous
none
time
systemat
manag
crv
infect
could
prove
reward
term
outcom
improv
hematolog
patient
